Abstract: c-Myc is one of the most frequently deregulated oncogenes in human cancers, and recent studies showed that even brief inactivation of Myc can be sufficient to induce tumor regression or loss. Consequently, inactivation of Myc provides a novel therapeutic opportunity and challenge, as the dimerization of Myc with Max is crucial for its function. We applied two strategies to specifically target this coiled coil mediated interaction with interfering peptides: a dominant-negative human Max sequence (Max) and a peptide selected from a genetic library (Mip). Both peptides form coiled coils and were fused to an acidic extension interacting with the basic DNA-binding region of human Myc. The genetic library was obtained by semi-rational d...
Identifying and targeting cancer cell components that play non-degenerate and non-redundant function...
Identifying and targeting cancer cell components that play non-degenerate and non-redundant function...
Developing therapeutics to effectively inhibit the MYC oncoprotein would mark a key advance towards ...
Abstract: c-Myc is one of the most frequently deregulated oncogenes in human cancers, and recent stu...
c-Myc is a transcription modulator protooncogene. When overexpressed, it becomes an important contri...
c-Myc is a transcription modulator proto-oncogene. When overexpressed, it becomes an important contr...
The rational design of inhibitors of the bHLH-ZIP oncoprotein c-Myc is hampered by a lack of structu...
Deregulated CMYC gene causes cell transformation and is often correlated with tumor progression and ...
Myc is a popular transcription factor that is found in about 30% of human cancers. Along with being ...
Myc (avian myelocytomatosis viral oncogene homolog) represents one of the most sought after drug tar...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2019Cat...
Our work is focused in the broad area of strategies and efforts to inhibit protein-protein interacti...
Compounds that selectively prevent or disrupt the association between the c-Myc oncoprotein and its ...
The transcription factor Max is a basic-helix-loop-helix leucine zipper (bHLHLZ) protein that forms ...
bHLH and bHLHZip are highly conserved structural domains mediating DNA binding and specific protein-...
Identifying and targeting cancer cell components that play non-degenerate and non-redundant function...
Identifying and targeting cancer cell components that play non-degenerate and non-redundant function...
Developing therapeutics to effectively inhibit the MYC oncoprotein would mark a key advance towards ...
Abstract: c-Myc is one of the most frequently deregulated oncogenes in human cancers, and recent stu...
c-Myc is a transcription modulator protooncogene. When overexpressed, it becomes an important contri...
c-Myc is a transcription modulator proto-oncogene. When overexpressed, it becomes an important contr...
The rational design of inhibitors of the bHLH-ZIP oncoprotein c-Myc is hampered by a lack of structu...
Deregulated CMYC gene causes cell transformation and is often correlated with tumor progression and ...
Myc is a popular transcription factor that is found in about 30% of human cancers. Along with being ...
Myc (avian myelocytomatosis viral oncogene homolog) represents one of the most sought after drug tar...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2019Cat...
Our work is focused in the broad area of strategies and efforts to inhibit protein-protein interacti...
Compounds that selectively prevent or disrupt the association between the c-Myc oncoprotein and its ...
The transcription factor Max is a basic-helix-loop-helix leucine zipper (bHLHLZ) protein that forms ...
bHLH and bHLHZip are highly conserved structural domains mediating DNA binding and specific protein-...
Identifying and targeting cancer cell components that play non-degenerate and non-redundant function...
Identifying and targeting cancer cell components that play non-degenerate and non-redundant function...
Developing therapeutics to effectively inhibit the MYC oncoprotein would mark a key advance towards ...